Patents Assigned to Physician's Seal, LLC
-
Patent number: 10751323Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.Type: GrantFiled: March 11, 2019Date of Patent: August 25, 2020Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Daniel Hassan
-
Patent number: 10688059Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.Type: GrantFiled: September 4, 2018Date of Patent: June 23, 2020Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Noreen Hassan
-
Patent number: 10500280Abstract: A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.Type: GrantFiled: June 15, 2018Date of Patent: December 10, 2019Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
-
Patent number: 10342873Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.Type: GrantFiled: May 4, 2017Date of Patent: July 9, 2019Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
-
Patent number: 10226447Abstract: An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin. The dosage form is effective to release melatonin therefrom for at least six hours after oral ingestion.Type: GrantFiled: January 23, 2017Date of Patent: March 12, 2019Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Daniel Hassan
-
Patent number: 10143654Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.Type: GrantFiled: December 7, 2016Date of Patent: December 4, 2018Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan
-
Patent number: 10085947Abstract: An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body.Type: GrantFiled: September 3, 2014Date of Patent: October 2, 2018Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Noreen Hassan
-
Publication number: 20170319476Abstract: A composition includes a therapeutically effective oral pharmaceutical dosage form that becomes buoyant upon contact with gastric fluid. The dosage form includes an active ingredient combination including an amino acid source and a zinc source, an anionic polymer, an effervescent agent, and a pH buffer. The dosage form is effective for releasing the active ingredient combination while buoyant on gastric fluid.Type: ApplicationFiled: May 4, 2017Publication date: November 9, 2017Applicant: Physician's Seal, LLCInventors: Daniel Hassan, Syed M. Shah, Fred Hassan, Christopher Diorio
-
Publication number: 20170319697Abstract: A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.Type: ApplicationFiled: May 4, 2017Publication date: November 9, 2017Applicant: Physician's Seal, LLCInventors: Syed M. Shah, Christopher Diorio, Daniel Hassan, Fred Hassan
-
Publication number: 20170231940Abstract: A composition includes a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates. The individual particulates respectively have: a core including an active ingredient combination of an L-carnitine and a nootropic substance and a release controlling polymer over the core that substantially prevents release of the active ingredients in stomach acid and permits release of the active ingredients in an intestinal pH environment. The composition may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body and/or cognitive impairment.Type: ApplicationFiled: May 4, 2017Publication date: August 17, 2017Applicant: Physician's Seal, LLCInventors: Syed M. Shah, Noreen Hassan, Christopher Diorio, Fred Hassan
-
Patent number: 9549900Abstract: A method of treating a human subject in need of melatonin therapy includes administering to a human subject a compressed tablet comprising melatonin, citric acid, and a cellulosic polymer. The melatonin, citric acid, and cellulosic polymer combine after ingestion to form an acidic hydrogel that dissolves the melatonin and is effective to provide a first release dose of melatonin for assisting in inducement of sleep and a subsequent sustained release dose of melatonin for assisting in sustaining sleep while in the human subject's gastrointestinal tract.Type: GrantFiled: November 16, 2015Date of Patent: January 24, 2017Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Daniel Hassan
-
Patent number: 9532952Abstract: Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.Type: GrantFiled: May 6, 2016Date of Patent: January 3, 2017Assignee: Physician's Seal, LLCInventors: Syed M. Shah, Daniel Hassan, Christopher Diorio, Fred Hassan